{"id":239136,"date":"2010-01-27T13:32:25","date_gmt":"2010-01-27T18:32:25","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/01\/27\/selling-a-health-business-in-the-developing-world-call-abbott\/"},"modified":"2010-01-27T13:32:25","modified_gmt":"2010-01-27T18:32:25","slug":"selling-a-health-business-in-the-developing-world-call-abbott","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/239136","title":{"rendered":"Selling a Health Business in the Developing World? Call Abbott"},"content":{"rendered":"

\"WorldOn Abbott’s earnings call today, an analyst asked CEO Miles White about the company’s short-term M&A strategy. “Is your plate full?” the analyst asked, according to a transcript from Thomson Reuters.<\/p>\n

The company cut a deal last fall to buy Solvay’s vaccines business for about $7 billion<\/a>. That followed a January deal to buy Advanced Medical Optics, an eye-care company, for more than $1 billion<\/a>.<\/p>\n

But there are still some deals that would interest the company, White said:<\/p>\n

\n

I wouldn’t tell you we’re so busy at capacity that we can’t do anything else. … We’re keeping our eyes open for things that would be additions to or expansions of our existing franchises or businesses around the world. We’re mindful of further geographic footprint. I have mentioned before the emerging markets are clearly a priority for us, and our footprint there [is] important to us in a number of businesses.<\/p>\n<\/blockquote>\n

Abbott may see some familiar faces as it travels to distant lands. In the past few years, Pfizer<\/a>, Sanofi-Aventis<\/a> and GlaxoSmithKline<\/a> have all made acquisitions or licensing deals to expand their business in emerging markets.<\/p>\n

Map via Wikimedia Commons<\/em><\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

On Abbott’s earnings call today, an analyst asked CEO Miles White about the company’s short-term M&A strategy. “Is your plate full?” the analyst asked, according to a transcript from Thomson Reuters. The company cut a deal last fall to buy Solvay’s vaccines business for about $7 billion. That followed a January deal to buy Advanced […]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-239136","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/239136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=239136"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/239136\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=239136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=239136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=239136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}